Haemonetics Corporation (NYSE:HAE) Shares Acquired by KBC Group NV

KBC Group NV boosted its position in Haemonetics Corporation (NYSE:HAE) by 19.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,417 shares of the medical instruments supplier’s stock after buying an additional 401 shares during the period. KBC Group NV’s holdings in Haemonetics were worth $154,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HAE. Charles Schwab Investment Management Inc. grew its position in Haemonetics by 1.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 551,193 shares of the medical instruments supplier’s stock valued at $43,037,000 after buying an additional 8,477 shares during the last quarter. Arizona State Retirement System grew its position in Haemonetics by 1.2% in the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock valued at $1,160,000 after buying an additional 181 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Haemonetics in the 4th quarter valued at $19,002,000. Ashton Thomas Private Wealth LLC purchased a new position in Haemonetics in the 4th quarter valued at $284,000. Finally, AMG National Trust Bank purchased a new position in Haemonetics in the 4th quarter valued at $746,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Robert W. Baird started coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an “outperform” rating and a $87.00 target price on the stock. Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Wednesday, June 25th. Raymond James Financial restated a “strong-buy” rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, JMP Securities restated a “market outperform” rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and an average target price of $96.80.

Haemonetics Trading Up 0.8%

NYSE:HAE opened at $76.85 on Monday. The company has a market capitalization of $3.69 billion, a PE ratio of 23.22, a price-to-earnings-growth ratio of 1.25 and a beta of 0.39. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. Haemonetics Corporation has a 52-week low of $55.30 and a 52-week high of $94.99. The stock has a fifty day simple moving average of $69.41 and a 200-day simple moving average of $67.93.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.90 EPS. On average, equities research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.